McGaffin Kenneth R, Chrysogelos Susan A
Vincent T Lombardi Cancer Center, Department of Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington, DC 20007, USA.
J Mol Endocrinol. 2005 Aug;35(1):117-33. doi: 10.1677/jme.1.01813.
Reduction of epidermal growth factor receptor (EGFR) mRNA and protein by 1,25-dihydroxyvitamin D3 has been documented in MCF7, T47D, and BT549 breast cancer cells. In the present report, functional mapping of the EGFR promoter in BT549 cells has revealed a sequence of DNA between nucleotide positions -536 and -478 that resembles a consensus vitamin D response element (VDRE) and confers a vitamin D response upon both the homologous and a minimal heterologous promoter. In vitro footprinting and gel shift assays demonstrate the presence of an unidentified nuclear factor that is required for strong binding of the vitamin D receptor (VDR) to this putative VDRE. An Sp1 binding site was also identified in close proximity and shown to bind Sp1 from nuclear extract. Mutational analysis and functional studies using a minimal heterologous promoter provide evidence that the VDR in concert with an unknown nuclear partner mediates basal EGFR repression through displacement of Sp1 which is augmented in the presence of a ligand.
1,25 - 二羟基维生素D3可使MCF7、T47D和BT549乳腺癌细胞中的表皮生长因子受体(EGFR)mRNA和蛋白水平降低,这一点已有文献记载。在本报告中,对BT549细胞中EGFR启动子的功能定位揭示了核苷酸位置-536至-478之间的一段DNA序列,该序列类似于共有维生素D反应元件(VDRE),并赋予同源和最小异源启动子维生素D反应性。体外足迹法和凝胶迁移试验表明存在一种未知的核因子,它是维生素D受体(VDR)与该假定VDRE紧密结合所必需的。还在紧邻位置鉴定出一个Sp1结合位点,并显示其可与核提取物中的Sp1结合。使用最小异源启动子进行的突变分析和功能研究提供了证据,表明VDR与一个未知的核伴侣协同作用,通过取代Sp1来介导基础EGFR的抑制作用,在配体存在时这种抑制作用会增强。